ABERNETHY MATT has filed 59 insider transactions across 2 companies since January 2023.
Most recent transaction: a gift of 2249 shares of NEUROCRINE BIOSCIENCES INC ($NBIX) on March 04, 2026.
Activity breakdown: 0 open-market purchases and 19 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 4, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | G | Common Stock | 2249 | $0.00 | 42,808.0000 | 102,500,000 | 4.99% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | F | Common Stock | 1210 | $124.12 | 39,110.0000 | 102,500,000 | 3.00% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Common Stock | 2241 | $0.00 | 40,320.0000 | 102,500,000 | 5.89% | 0.00% |
| Feb. 12, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | F | Common Stock | 1151 | $123.10 | 38,079.0000 | 102,500,000 | 2.93% | 0.00% |
| Feb. 12, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Common Stock | 2133 | $0.00 | 39,230.0000 | 102,500,000 | 5.75% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | F | Common Stock | 1385 | $124.12 | 40,291.0000 | 102,500,000 | 3.32% | 0.00% |
| Feb. 12, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Restricted Stock Unit | 2133 | $0.00 | 6,401.0000 | 102,500,000 | 24.99% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | F | Common Stock | 5378 | $124.12 | 44,881.0000 | 102,500,000 | 10.70% | 0.01% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | A | Common Stock | 9968 | $0.00 | 50,259.0000 | 102,500,000 | 24.74% | 0.01% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Common Stock | 2566 | $0.00 | 41,676.0000 | 102,500,000 | 6.56% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | A | Restricted Stock Unit | 7735 | $0.00 | 7,735.0000 | 102,500,000 | 9999.99% | 0.01% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | A | Stock Option | 44095 | $0.00 | 44,095.0000 | 102,500,000 | 9999.99% | 0.04% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Restricted Stock Unit | 2566 | $0.00 | 2,566.0000 | 102,500,000 | 50.00% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Restricted Stock Unit | 2241 | $0.00 | 4,484.0000 | 102,500,000 | 33.32% | 0.00% |
| Jan. 31, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | F | Common Stock | 1368 | $136.06 | 37,097.0000 | 102,500,000 | 3.56% | 0.00% |
| Jan. 31, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Common Stock | 2437 | $0.00 | 38,465.0000 | 102,500,000 | 6.76% | 0.00% |
| Jan. 31, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Restricted Stock Unit | 2437 | $0.00 | 0.0000 | 102,500,000 | 100.00% | 0.00% |
| May 29, 2025 | FATE THERAPEUTICS INC | $FATE | ABERNETHY MATT | Not found | A | Stock Option (Right to Buy) | 110000 | $0.00 | 110,000.0000 | 113,685,177 | 9999.99% | 0.10% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Restricted Stock Unit | 2566 | $0.00 | 5,132.0000 | 103,700,000 | 33.33% | 0.00% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Common Stock | 2566 | $0.00 | 36,127.0000 | 103,700,000 | 7.65% | 0.00% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 1352 | $116.85 | 34,775.0000 | 103,700,000 | 3.74% | 0.00% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Common Stock | 2241 | $0.00 | 37,016.0000 | 103,700,000 | 6.44% | 0.00% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 1206 | $116.87 | 35,810.0000 | 103,700,000 | 3.26% | 0.00% |
| Feb. 12, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | A | Stock Option | 45538 | $0.00 | 45,538.0000 | 103,700,000 | 9999.99% | 0.04% |
| Feb. 12, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | A | Restricted Stock Unit | 8534 | $0.00 | 8,534.0000 | 103,700,000 | 9999.99% | 0.01% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Restricted Stock Unit | 2241 | $0.00 | 6,725.0000 | 103,700,000 | 24.99% | 0.00% |
| Feb. 8, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Common Stock | 1860 | $0.00 | 34,541.0000 | 103,700,000 | 5.69% | 0.00% |
| Feb. 10, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 980 | $118.27 | 33,561.0000 | 103,700,000 | 2.84% | 0.00% |
| Feb. 8, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Restricted Stock Unit | 1860 | $0.00 | 0.0000 | 103,700,000 | 100.00% | 0.00% |
| Jan. 31, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Restricted Stock Unit | 2436 | $0.00 | 2,437.0000 | 103,700,000 | 49.99% | 0.00% |
| Jan. 31, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Common Stock | 2436 | $0.00 | 33,964.0000 | 103,700,000 | 7.73% | 0.00% |
| Jan. 31, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 1283 | $152.87 | 32,681.0000 | 103,700,000 | 3.78% | 0.00% |
| Aug. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 14100 | $150.38 | 31,528.0000 | 101,000,000 | 30.90% | 0.01% |
| Aug. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Common Stock | 14100 | $73.60 | 45,628.0000 | 101,000,000 | 44.72% | 0.01% |
| Aug. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Non-Qualified Stock Option | 14100 | $0.00 | 0.0000 | 101,000,000 | 100.00% | 0.01% |
| July 16, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 900 | $150.04 | 31,528.0000 | 101,000,000 | 2.78% | 0.00% |
| July 16, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Common Stock | 900 | $73.60 | 32,428.0000 | 101,000,000 | 2.85% | 0.00% |
| July 16, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Non-Qualified Stock Option | 900 | $0.00 | 14,100.0000 | 101,000,000 | 6.00% | 0.00% |
| May 14, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Non-Qualified Stock Option | 15000 | $73.60 | 30,000.0000 | 101,000,000 | 33.33% | 0.01% |
| May 15, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Non-Qualified Stock Option | 15000 | $73.60 | 15,000.0000 | 101,000,000 | 50.00% | 0.01% |
| May 15, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 15000 | $140.24 | 31,528.0000 | 101,000,000 | 32.24% | 0.01% |
| May 15, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Common Stock | 15000 | $73.60 | 46,528.0000 | 101,000,000 | 47.58% | 0.01% |
| May 14, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 15000 | $135.66 | 31,528.0000 | 101,000,000 | 32.24% | 0.01% |
| May 14, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | M | Common Stock | 15000 | $73.60 | 46,528.0000 | 101,000,000 | 47.58% | 0.01% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | A | Restricted Stock Unit | 8966 | $0.00 | 8,966.0000 | 101,000,000 | 9999.99% | 0.01% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | A | Stock Option | 45058 | $0.00 | 45,058.0000 | 101,000,000 | 9999.99% | 0.04% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 1352 | $132.85 | 31,528.0000 | 101,000,000 | 4.11% | 0.00% |
| Feb. 6, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 1280 | $142.19 | 29,434.0000 | 101,000,000 | 4.17% | 0.00% |
| Feb. 8, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 980 | $134.21 | 30,314.0000 | 101,000,000 | 3.13% | 0.00% |
| Jan. 31, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 1283 | $140.72 | 28,284.0000 | 101,000,000 | 4.34% | 0.00% |
| Aug. 21, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 2132 | $107.39 | 27,131.0000 | 98,900,000 | 7.29% | 0.00% |
| Feb. 13, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | A | Restricted Stock Unit | 10264 | $0.00 | 10,264.0000 | 98,900,000 | 9999.99% | 0.01% |
| Feb. 13, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | A | Stock Option | 63789 | $0.00 | 63,789.0000 | 98,900,000 | 9999.99% | 0.06% |
| Feb. 7, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 2030 | $102.33 | 24,333.0000 | 98,900,000 | 7.70% | 0.00% |
| Feb. 7, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 11491 | $102.40 | 24,333.0000 | 98,900,000 | 32.08% | 0.01% |
| Feb. 8, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 980 | $104.19 | 25,213.0000 | 98,900,000 | 3.74% | 0.00% |
| Feb. 6, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 1280 | $105.67 | 22,507.0000 | 98,900,000 | 5.38% | 0.00% |
| Feb. 7, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 12807 | $102.42 | 35,824.0000 | 98,900,000 | 26.34% | 0.01% |
| Jan. 31, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | ABERNETHY MATT | Chief Financial Officer | S | Common Stock | 1283 | $109.98 | 21,357.0000 | 98,900,000 | 5.67% | 0.00% |